Product image of Olmesartán/Hidroclorotiazida Teva (Olmesartan Medoxomil, Hydrochlorothiazide) supplied by GNH India

Olmesartán/Hidroclorotiazida Teva

Active Ingredient:
Olmesartan Medoxomil, Hydrochlorothiazide
Origin:
EU

Olmesartán/Hidroclorotiazida Teva (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Teva, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic, and is intended for adult patients. GNH India supplies Olmesartán/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Olmesartán/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan/hydrochlorothiazide is used in the management of high blood pressure through combined renin‑angiotensin blockade and diuresis.

  • Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
  • Edema associated with hypertension: enhances fluid excretion to reduce swelling.
  • Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in patients with hypertension.
  • Resistant hypertension: offers an additional therapeutic option when other regimens fail.

How It Works

  • Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combined effect lowers systemic vascular resistance and plasma volume, resulting in reduced arterial pressure.

Side Effects

Both components are generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Dizziness: mild to moderate light‑headedness, especially after the first doses.
  • Headache: transient headache that often resolves with continued therapy.
  • Fatigue: feeling of tiredness without a clear cause.
  • Electrolyte imbalance: mild reductions in potassium or sodium levels.
  • Increased urination: due to the diuretic effect of hydrochlorothiazide.

Serious or Rare Side Effects

  • Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care.
  • Severe electrolyte disturbances: marked hypokalemia or hyponatremia.
  • Acute kidney injury: sudden decline in renal function, particularly in patients with pre‑existing kidney disease.
  • Liver injury: rare cases of hepatitis or jaundice.
  • Severe hypotension: excessive drop in blood pressure leading to fainting or shock.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function: assess baseline kidney function and monitor periodically.
  • Electrolytes: check serum potassium and sodium levels before and during treatment.
  • Diabetes: monitor blood glucose as thiazides may affect glycemic control.
  • Gout: be aware of potential increase in serum uric acid.
  • Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional.
  • Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Avoid Interactions

Olmesartan/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid)

  • Aliskiren: concurrent use can increase risk of renal impairment and hyperkalemia.
  • Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
  • NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

  • Lithium: thiazides can raise lithium levels, requiring serum monitoring.
  • Antidiabetic agents: thiazides may reduce glucose control, necessitating dose adjustments.
  • ACE inhibitors or other ARBs: combined use increases risk of hyperkalemia and renal dysfunction.

Frequently Asked Questions

Olmesartán/Hidroclorotiazida Teva is a fixed‑dose combination of olmesartan medoxil, an angiotensin II receptor blocker, and hydrochlorothiazide, a thiazide diuretic. It is prescribed to lower high blood pressure, often when a single agent does not achieve target values, and may also help reduce fluid retention associated with hypertension.

Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing the hormone from causing blood vessels to narrow and reducing aldosterone‑driven sodium retention. This leads to vasodilation and lower systemic vascular resistance, contributing to a reduction in arterial pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure level, response to therapy, and any co‑existing medical conditions. The prescriber will select the strength and dosing schedule that best fits the individual’s therapeutic needs.

Olmesartan, an ARB, is generally contraindicated during pregnancy because of potential fetal toxicity, and hydrochlorothiazide is usually avoided unless clearly needed. Breastfeeding mothers should discuss risks with their healthcare provider, as the drugs may pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy, the olmesartan/hydrochlorothiazide combo offers additive blood‑pressure lowering through two complementary mechanisms—angiotensin II blockade and diuresis. This can achieve target pressures more efficiently than either agent alone, and may reduce pill burden versus separate prescriptions.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events can include angioedema, severe electrolyte disturbances (especially low potassium), acute kidney injury, and marked hypotension. Patients should seek immediate medical attention if they experience swelling of the face or throat, severe dizziness, or sudden loss of kidney function.

The combination should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any excipients, as well as in those with severe renal impairment, hyperkalemia, or a history of angioedema related to ARB therapy. Clinicians should also assess suitability in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT